Keri Schaubert will present at the 2nd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA Conference. Keri will join a panel discussing identifying the application process for the approval of a new drug, i.e., small molecule, new chemical entities, etc.
Rx Drugs (new drugs)
-
NDA (New Drug Application): definition, contents and regulatory overview
-
INDA (Investigational New Drug Application) aka “IND”
-
How does it differ from an NDA?
-
Accelerated approvals
-
Defining eligibility criteria for accelerated approval and priority reviews
-
What portions of approval submissions might FDA release and when?
-
Using advisory committees in the approval process
Biologics
-
How does the approval process for a biologic differ from that of a drug?
-
BLA (Biological Licensing Application): application and filing
-
How does a biologic differ from a drug?
-
Which products require BLAs instead of NDAs?
-
Why is it a “license,” rather than an “approved application”?